SCHEMBL23033249

SCHEMBL23033249

CC(=O)Nc1ccc(CNCCc2ccc(F)c(Cl)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
IDO1 P14902 1/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HTT P42858 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.46
SCN8A Q9UQD0 1/20 0.46
CNR1 P21554 2/20 0.45
BRAF P15056 1/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2C9 P11712 1/20 0.45
SLC2A1 P11166 1/20 0.45
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23033084 0.90 IDO1 (0.49) SMN1; SMN2IDO1MEN1KMT2AMAPT
SCHEMBL23033247 0.88 MEN1 (0.56) SMN1; SMN2IDO1MEN1KMT2ASCN8A
SCHEMBL23033397 0.84 CNR1 (0.61) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL21114827 0.84 HDAC1 (0.64) SMN1; SMN2MEN1KMT2AMAPTNPC1
SCHEMBL29521416 0.84 HDAC1 (0.64) SMN1; SMN2MEN1KMT2AMAPTNPC1
SCHEMBL23033082 0.82 RAF1 (0.54) SMN1; SMN2MAPTLMNAPOLB
SCHEMBL23033415 0.81 SMN1; SMN2 (0.47) SMN1; SMN2IDO1MEN1KMT2AMAPT
SCHEMBL23033398 0.79 RHOC (0.56) MEN1KMT2AALDH1A1HTTSCN8A
SCHEMBL23033245 0.78 SCN8A (0.49) SMN1; SMN2MEN1KMT2AMAPTALDH1A1
SCHEMBL5183171 0.77 MEN1 (0.77) SMN1; SMN2IDO1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210052519-A1 Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation ACELOT,INC (US) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052519-A1 Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation HTT, TARDBP, SNCA SMN1; SMN2 232/4885IDO1 2581/4885MEN1 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.